Plain-English translation of NCT06707259 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cell therapy called CB IL-10/IL-15 CD19-CAR NK cells, which are special immune cells grown in the laboratory from cord blood. These cells are designed to recognize and attack B-cell lymphoma cancer cells. The study will evaluate whether this treatment is safe and how well it works for patients whose lymphoma has come back or didn't respond to previous treatments.
Many patients with B-cell lymphoma stop responding to standard chemotherapy and other treatments, leaving them with limited options. This medication represents a new approach using engineered immune cells to fight the cancer in a different way.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the new immune cells on three separate days (day 0, day 3, and day 6) through an IV. The trial will start with lower doses in the first group of patients and gradually increase to find the best dose—this is called dose escalation. You'll be closely monitored for side effects and to see how well the treatment works, with follow-up visits to check your response to the treatment over time.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Enrollment target
~24 participants
Started
December 2024
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenbin Qian, Professor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.